Medipharm Labs Corp T.LABS

The success of LABS

[subaru1i]

Is absolutely no longer a question of if. But it now is merely a question of when and in general terms I believe 2024 will finally be our year that this stock price breaks out big time. You can't argue with the launch of generic epidiolex for the US market this year!

[okgonow]

  not if the courts in the US keep ruling like this: From Jan of this year   Jazz Pharmaceuticals has rebuffed attempts by rival Teva Pharmaceuticals to legally disqualify its patent for Epidyolex, a cannabis-based drug worth hundreds of millions of dollars a year. The legal dispute between the two pharmaceutical heavyweights began when several companies, including

[Solid1]

If the generic drug is a completely new treatment method, nothing stands in the way of approval! The active ingredients of Epidiolex are not patentable. JAZZ's patents relate to the treatment of epilepsy. Epidiolex is a brand name, the active ingredient is CBD. Medipharm and its partner can refer to the active ingredients of Epidiolex and still no patent is infringed. 

[Solid1]

Teva tried to market a generic version of Epidiolex for the treatment of epilepsy, but was rejected by the courts.

[Solid1]

And let's not forget Dr. Yasmin Hurd, a pioneer in addiction research who has been working with the FDA on the use of CBD since early 2023. Dr. Yasmin Hurd has also worked with Medipharm Labs (but that was a while ago). A very interesting development for me, especially in the area of opiate addiction and CBD.... John Hopkins has used Epidiolex in opiate addiction research, which the generic in

[subaru1i]

The application of a generic form of epidiolex for opiate addiction is very interesting and recall that the CEO did state that some of the data for the ANDA was from another party and I am now wondering if that is for the SEDDS technology used in a generic version of Epidiolex.  Those data points now compiled together at least box in for me

[alleyesonme]

The ANDA could be for the current form of epidiolex and its approved indications, whereas the 505b2 is CBDaka cannabidol , epidiolex, for a new indication, dosage as a tab, therefore not infringing on patents, I believe strongly the 505b2 will be MPL's first commercial drug in the US..and it's cannabidol...I also believe when Keith referred to "preparing for epidiolex launch in the U

[subaru1i]

The CEO made the statement that they will be launching generic epidiolex for the US market this year! 

[subaru1i]

I personally believe they could be using the SEDDS technology which is a totally different delivery format than non-generic version of epidiolex